Pacira Pharmaceuticals Inc. said Thursday it has named Scott Braunstein as chief operation officer and Richard Scranton as chief scientific officer. Scranton will head research, while leading communications and market access for Exparel, the company’s non-opioid treatment for managing post-surgical pain. Shares were not yet active premarket, but have gained 34% in 2017, while the S&P 500 has gained 17%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Wall Street Journal: China continues ‘unfair’ trade practices, says U.S. trade representative - November 20, 2018
- MarketWatch First Take: Gloomy forecasts slash tech valuations as Silicon Valley chokes on smoke - November 20, 2018
- The Wall Street Journal: Apple could provide veterans with access to electronic medical records - November 20, 2018